Tessie

1 x 15 ml

Oral solution

Active substance

Tasipimidine (Tasipimidine sulfate) : 0,3 mg/ml

ATC code

QN05CM96 Tasipimidine

QN05CM Other hypnotics and sedatives

QN05C Hypnotics and sedatives

QN05 Psycholeptics

QN Nervous system

Species

Dogs

Indications

Short term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.

Dose to be administered and administration route

Oral use.

The product is intended for short term use but it can be safely administered for up to 9 consecutive days.

The product should be administered orally at a dose of 0.1 ml/kg bodyweight (equivalent to 30 mcg/kg) in situational anxiety and fear in dogs triggered by noise or owner departure.

If the product is intended for use in situations where the dog is meant to be alone following the administration, a test dose should be given. Following administration of the test dose the dog should be observed for 2 hours to make sure the selected dose of the product is not associated with adverse reactions and that it is safe for the treated dog to be left alone (see section 3.5).

Do not feed the dog for one hour before to one hour after treatment as absorption may be delayed. A small treat can be given to ensure that the dog swallows the solution. Water can be freely available.

Observe the dog. If the fear triggering event continues and the dog starts to show signs of anxiety and fear again, re-dosing can be done when at least 3 hours has passed from the previous dose. The product can be dosed up to 3 times within every 24 hours.

Dose reduction

If the dog appears drowsy, its movements are uncoordinated or it responds to its owner’s call abnormally slowly after receiving treatment, the dose could be too high. The subsequent dose should be reduced to 2/3 of the volume of the previous dose, corresponding to 20 mcg/kg bodyweight. Dose reduction should be implemented following veterinary advice only.

Anxiety and fear triggered by noise:

The first dose should be given one hour before expected start of an anxiety triggering stimulus, as soon as the dog shows the first signs of anxiety, or when the owner detects a typical stimulus for eliciting anxiety or fear in the respective dog.

Anxiety and fear triggered by owner departure:

The dose should be given one hour before expected owner departure.

Instructions for administration:

Adverse reactions

Dogs:

Very common

(> 1 animal / 10 animals treated):

Emesis

Lethargy

Common

(1 to 10 animals / 100 animals treated):

Behavioural disorder (Barking, Avoidance, Increased reactivity)

Diarrhoea, Gastroenteritis, Nausea

Hypersensitivity reaction

Leucopenia

Ataxia, Sedation, Somnolence, Disorientation

Urinary incontinence

Anorexia, Pale mucous membranes, Polydipsia

Undetermined frequency

(cannot be estimated for the available data):

Decreased heart rate¹, Low blood pressure¹

Decreased body temperature¹

¹observed in non-anxious animals

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.